Medical device for pulsatile transdermal delivery of biologically active agents

• US 4,698,062 A
• Filed: 10/30/1985
• Issued: 10/06/1987
• Est. Priority Date: 10/30/1985
• Status: Expired due to Fees

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Gale, Robert M., Berggren, Randall
• Primary Examiner(s): Rosenbaum, C. Fred
• Assistant Examiner(s): Smith, Jr., Jerome R.
• Application Number:
  US06/792,941
• Time in Patent Office: 706 Days
• Field of Search: 604/890-893, 604/896, 604/897, 424/19-22, 424/28
• US Class Current: 424/449
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• CPC Class Codes: A61M 35/00 Devices for applying media, e.g. remedies, on the human body devices for handling toiletry or cosmetic substances A45D; absorbent pads, e.g. swabs, A61F13/15

Abstract

A medical device and method for the pulsatile administration of a drug through intact skin at a first steady state flux during a first delivery period and a second steady state flux during a second delivery period, said first flux being substantially higher than said second flux; said first and second delivery periods comprising a substantial portion of a predetermined administration period. The device comprises a reservoir of said drug containing an amount of drug sufficient to administer drug at said first and second steady state fluxes during administration period; a reservoir of a skin permeation enhancer for said drug; said reservoir containing an amount of said permeation enhancer sufficient to permit administration of said drug at said first flux only through said first delivery period; and means for maintaining said device on the skin in drug and permeation enhancer transferring relationship thereto a preferred embodiment delivering nitroglycerin and employing ethanol as a permeation enhancer. The device contains means for controlling the maximum delivery rate of one of said drug or enhancer. A preferred embodiment provides for the pulsatile delivery of nitroglycerin.

Claims

1. A medical device for the pulsitile administration of a drug through intact skin at a first steady state flux during a first delivery period and a second steady state flux during a second delivery period, said first and second delivery periods comprising a substantial portion of a predetermined administration period;

said device comprising;

(a) a reservoir of said drug containing an amount of drug at least sufficient to administer drug at said first and second steady state fluxes throughout said administration period, said first steady state flux being substantially higher than said second steady states flux

(b) a reservoir of a skin permeation enhancer for said drug;

said reservoir containing an amount of permeation enhancer (i) sufficient to permit administration of said permeation enhancer at permeation enhancing fluxes through said first delivery period and (ii) insufficient to permit administration of said permeation enhancer at permeation enhancing fluxes during the remainder of said administration period; and

(c) means for maintaining said device on the skin in drug and permeation enhancer transferring relationship thereto;

whereby a pulsitile drug administration pattern, having a first flux substantially higher than the flux of drug through untreated skin during said first period and a second, substantially lower flux during said second delivery period, will be obtained.

2. The device of claim 1 wherein said drug reservoir and permeation enhancer reservoir is a common reservoir comprising drug and permeation enhancer dispersed within a carrier.

3. The device of claim 1 further comprising release rate controlling means for one of said drug and permeation enhancer disposed between the respective reservoir and the skin.

4. The device of claim 3 wherein said release rate controlling means controls the release rate of said permeation enhancer and is disposed between the permeation enhancer reservoir and the drug reservoir and in the flow path of permeation enhancer from said enhancer reservoir to the skin.

5. The device of claim 4 wherein said drug reservoir comprises the skin contacting surface of the device.

6. The device of claim 5 wherein said drug reservoir comprises said drug dispersed within an adhesive and said drug reservoir comprises the means for maintaining the device on the skin.

7. The device of claim 2 further comprising release rate controlling means for one of said drug and permeation enhancer disposed between the common reservoir and the skin.

8. The device of claim 7 wherein said means for maintaining the device on the skin comprises a contact adhesive on the skin contacting surface of the device.

9. The device of claim 3 wherein said release rate controlling means controls the release rate of said drug during said first delivery period and is disposed between said drug reservoir and said enhancer reservoir in the path of drug flow from said drug reservoir to the skin.

10. The device of claim 7 wherein said release rate controlling means controls the rate of release of said permeation enhancer.

11. The device of claim 7 wherein said release rate controlling means controls the release rate of said drug during said first delivery period.

12. The device of claim 1 wherein said drug is permeable through normal human skin at therapeutic fluxes.

13. The device of claim 12 wherein said drug is selected from the group consisting of analgesics, anti-emetics, anti-inflammatories, anti-anginals and anti-spasmodics.

14. The device of claim 1 wherein said drug is nitroglycerin and said permeation enhancer is ethanol.

19. The delivery device of claim 1 where each of said first and second delivery periods is at least 2 hours and said administration period is at least about 16 hours.

20. The delivery device of claim 19 wherein each of said first and second delivery periods is at least 6 hours.

21. The delivery device of claim 20 wherein said administration period is at least about 24 hours.

15. A medical device for the pulsatile administration of nitroglycerine through intact skin at a first steady state flux during a first delivery period, and a second steady state flux during a second delivery period, said first flux being higher than said second flux, said first and second delivery periods comprising a substantial portion of a predetermined administration period, said device comprising:

(a) a nitroglycerin reservoir;

(b) an ethanol reservoir; and

(c) means for controlling the release rate of said ethanol;

said device being characterized by having a J_device for nitroglycerin of at least about 28 μ

g/cm² /hr, a J_device for ethanol in the range of 300-750 μ

g/cm² /hr, said ethanol reservoir containing that amount of ethanol required to allow the activity of the ethanol in the reservoir to drop below about 0.2 at the end of said first delivery period and said nitroglycerin reservoir containing sufficient nitroglycerin to supply nitroglycerin at said first and second steady state fluxes at least until the expiration of said predetermined administration period.

16. The device of claim 15 wherein said first delivery period is at least 2 hours, said second delivery period is at least 2 hours, and said predetermined administration period is at least about 16 hours.

17. The delivery device of claim 16 wherein each of said first and second delivery periods is at least 6 hours.

18. The delivery device of claim 17 wherein said administration period is at least about 24 hours.

22. The device of claim 15 wherein said nitroglycerin reservoir and said ethanol reservoir comprises a common reservoir of nitroglycerin and ethanol in a carrier having solubility for nitroglycerin and ethanol of no more than about 5 μ

g/gm.

23. The device of claim 15 wherein said rate controlling means is formed from ethylene vinyl acetate copolymer having a vinyl acetate content from about 11-18%.

24. The device of claim 22 wherein said rate controlling means is formed from ethylene vinyl acetate copolymer having a vinyl acetate content of from about 11-18%.

25. A method for pulsatile transdermal drug delivery from a medical device applied to the skin during an administration period which comprises:

(a) coadministering a drug and a permeation enhancer for the drug from said medical device during a first delivery period; and

(b) thereafter administering said drug and no more than an enhancement ineffective amount of said permeation enhancer from said device for a second delivery period, said first and second period each being at least about 2 hours, said first and second periods comprising a substantial portion of said administration period.

26. The method of claim 25 wherein said administration period is at least about 16 hours.

27. The method of claim 25 wherein said first and second periods are each at least about 6 hours and said administration period is at least about 24 hours.

28. The method of claim 25 wherein said drug is nitroglycerin, said enhancer is ethanol, the activity of said ethanol in the device is above about 0.2 during said first period and below about 0.2 during said second period.

29. The method of claim 28 wherein the activity of said nitroglycerin in the device is maintained at unit activity substantially throughout said administration period.

30. A method for pulsatile transdermal delivery of a drug in which comprise maintaining a source of drug in drug transmitting relationship to the skin and delivering said drug through skin from said source at a first rate substantially higher than the maximum rate at which said drug permeates through untreated intact skin and thereafter administering said drug at a second rate no greater than the rate at which said drug permeates through untreated skin.

31. The method of claim 30 wherein said first and second periods are at least 2 hours.

32. The method of claim 31 wherein said first and second periods are at least 6 hours.

33. The method of claim 30 wherein said drug is nitroglycerin.

34. The method of claim 31 wherein said drug is nitroglycerin.

35. The method of claim 32 wherein said drug is nitroglycerin.